Where to Buy Lab-Tested DSIP: 7 Purity and Identity Checks for the One Peptide an FDA Panel Declined to Recommend

DSIP is nine amino acids, all of them common, which means a 99% purity certificate does not tell you the vial contains DSIP. Mass spectrometry near 848.8 daltons does. That is the whole of the buyer's problem here.

This page is the sourcing walkthrough. DSIP sits in the cognitive and neuroprotective peptides category, vendor listings and per-milligram pricing sit on the DSIP compound page, and the evidence picture — the 1977 rabbit experiment behind the name, the 1987 trial that came back null, the missing receptor — is in DSIP: the peptide named after an effect its best human trial could not find. Read that one for whether it works. Read this one for whether what arrives is what you ordered.

What is DSIP, and why does source quality matter?

DSIP is an endogenous nonapeptide — Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, or WAGGDASGE — found in the hypothalamus and cerebrospinal fluid, carrying CAS 62568-57-4 and a molecular weight of 848.8 g/mol. Source quality matters for a reason specific to its size: nine residues of common amino acids give DSIP a composition that overlaps other small neuropeptides, so mass is the only reliable way to know what is in a vial, and a purity percentage is not a mass.

Two rows in that table do more work at the checkout page than the rest of the compound put together. The length row is the verification problem: nine residues is short, every amino acid in the sequence is a common one, and short peptides are difficult to tell apart by purity testing alone.

The "also known as" row is the research problem. In FDA compounding documents this compound appears as emideltide, not as DSIP, and that naming split has a practical consequence — searching the regulatory record for "DSIP" returns nothing at all, because the paperwork does not use the word. A buyer trying to check a vendor's regulatory claims under the name on the vial will find an empty result and may read it as an absence of controversy. It is not. It is the wrong search term.

What is the regulatory status of DSIP, and why is it filed as emideltide?

DSIP is approved nowhere, and as of August 2026 no compounding route exists. It came off FDA's 503A Category 2 list in the April 2026 reclassification, then went before the Pharmacy Compounding Advisory Committee on 23–24 July 2026 under the name emideltide, nominated for insomnia, narcolepsy and opioid use disorder. Of seven peptides reviewed across those two days, the committee recommended six. Emideltide was the only rejection, on a vote of 6 in favour, 7 against, 1 abstention, with reviewers citing a lack of both safety and efficacy data.

That result deserves weight precisely because of what it sits next to. The same committee, on the same days, backed BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon — several of them over objections from FDA's own reviewers, as STAT News reported on 24 July 2026. A panel willing to advance compounds on thin evidence still would not advance this one. For a buyer, that is a more informative signal than any single trial, because it is a comparative judgement made by the same people on the same afternoon.

The vote is advisory. FDA has not completed rulemaking on any of the seven, so nothing has changed in law for the six that were recommended either, and a vendor page presenting a recommendation as an approval has misread the process in both directions. Our FDA peptide regulation timeline sets out the full sequence.

On sport, DSIP is not named on the WADA Prohibited List (2026 List, checked August 2026).

The last row is the one that costs money. A compounding nomination is not a marketing application, an advisory vote is not a decision, and the vote that happened went against this compound.

What does "lab tested" actually prove for a nine-amino-acid peptide?

"Lab tested" proves very little about a DSIP vial unless the test named is mass spectrometry. Nine amino acids, all of them common, means HPLC reports the proportion of a sample that is a single species without identifying which species, so a 99% purity figure is entirely compatible with a different small neuropeptide. Mass spectrometry showing a mass near 848.8 daltons is not one check among several for this compound. It is the whole test.

That distinction is worth holding onto, because "lab tested" is a phrase vendors use and buyers hear as a single guarantee. It is not one claim, it is a family of claims, and they answer different questions.

One caveat applies to the whole published-certificate dataset, and on this compound it has extra force. Published certificates are the ones vendors chose to publish, which makes the sample selection-biased rather than a random market survey — and for a nine-residue peptide, a certificate reporting only HPLC purity does not establish that the vial contains DSIP at all. The method background sits in what HPLC testing can and cannot tell you, mass spectrometry for peptides and how to read peptide lab test results.

7 things to check before ordering DSIP

Seven checks cover DSIP, and the first carries most of the weight: a batch-matched mass spectrum reading near 848.8 daltons. After that come the sequence and formula written on the certificate, CAS 62568-57-4 with the emideltide naming test, third-party HPLC from a named laboratory, net peptide content as its own line, an LAL endotoxin result, and the product page read against what the record actually says about this compound.

1. A batch-matched mass spectrum near 848.8 daltons. On a nonapeptide this is not one check among several, it is the check, because short peptides are difficult to distinguish from one another by purity testing and mass is the only property on a certificate that identifies the molecule. Insist on a result tied to your lot rather than a specimen certificate from an earlier batch, which is one of the standard problems catalogued in red flags in peptide certificates of analysis.

2. The sequence and formula written out, not just the name. A certificate should carry WAGGDASGE and C₃₅H₄₈N₁₀O₁₅, because a name on a label is not a specification when the compound's composition overlaps other small neuropeptides. A vendor who publishes the sequence has committed to a molecule; a vendor who publishes only "DSIP 5mg" has committed to a word, and the word is the part of this compound with the weakest connection to its evidence.

3. CAS 62568-57-4 on the label, and whether the vendor knows the compound is emideltide. A CAS matching nothing, or none given, tells you the listing was assembled from other listings. The naming test goes further: FDA compounding documents call this compound emideltide, so a page citing "FDA review" without naming emideltide has not read the file it is citing, and a page whose regulatory section is empty may simply have searched the wrong word.

4. Third-party HPLC from a named laboratory, with the limit stated in the same breath. Require the laboratory to be named, since an unattributed document is a claim rather than a measurement — the point third-party peptide testing labs makes at length — and read the current per-compound figure live on the Purity Index rather than trusting a number quoted in vendor prose. Then hold the ceiling: high purity on a 9-mer is compatible with the wrong molecule.

5. Net peptide content as a separate line, which matters more here than on most compounds. Purity is a proportion and net content is a quantity, the distinction net peptide content exists to make. It bites harder on DSIP because community practice doses in micrograms — a 200 to 500 mcg convention — so the salt and water fraction of a vial is a proportionally larger share of a measured dose than it would be at milligram doses.

6. An LAL endotoxin result on the same batch. Community practice with this compound is subcutaneous injection, so pyrogen load is a live question rather than a formality, and an absent LAL result means the batch was not tested rather than that it passed. Ask for the result on your lot number, not a house statement that the product "meets endotoxin standards".

7. The product page read against the record, plus shop and price. A page presenting delta-wave sleep as an established human effect is restating a 1977 rabbit EEG finding; a page omitting that the best-controlled human trial found improvement "of little clinical significance" has left out the compound's most important result; a page describing the July 2026 process as pending approval has inverted a 6–7–1 rejection. Screen the vendor with how to spot a scam peptide shop and read community-verified shop reviews alongside the documents.

Rows two, three and seven have no laboratory component at all. They are read off the product page before any money changes hands, and on this compound they catch the failure mode a certificate cannot: a vendor selling a name rather than a molecule.

Where does DSIP rank on Peptigrity's lab test database?

DSIP's per-compound purity index score, contributing test count and laboratory count are read live from the Purity Index rather than fixed on this page, and the price page publishes shops in stock with the median and lowest price per milligram on the same live basis. Peptigrity tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified August 2026). Trust scores weight community reviews and independently verified HPLC purity equally, at 50% each.

That is a deliberate choice rather than a gap. A purity number quoted in prose ages the moment the next certificate lands, and on a compound where the purity figure is the least informative document in the file, fixing one in text would give it more weight than it earns. Individual certificates are searchable batch by batch in the independent lab tests database, and no financial relationship influences the ranking.

On cost, DSIP price data publishes shops in stock with the median and lowest price per milligram and the vial size behind the lowest figure. Read it within a single vial-size band, because fixed per-vial costs push the per-milligram figure down as fill size rises, which makes a large vial look like a better product rather than simply a bigger one. Then convert to what you will actually inject: at a 200 to 500 mcg community dose, a per-milligram price is several doses rather than one, so the cost per administration and the cost per milligram are different numbers. Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing.

Melatonin is the honest comparator on that table, and it is the row that reframes the purchase: an over-the-counter compound with a large evidence base and a modest effect sits beside a research chemical with one negative controlled trial and a name. The three-way comparison across the research compounds is in peptides for sleep: DSIP, Epithalon and Pinealon.

The trial that would settle this would measure the one thing self-report cannot.

Read the last row against the rest of this page. The requirement a trial would place on its own investigational material — characterised, mass-verified, known — is exactly the requirement a buyer is being asked to meet with a single document and no equipment.

Frequently Asked Questions

What purity standard should DSIP meet?

Read the current per-compound figure live on the Purity Index rather than against a vendor's "above 99%" promise, because purity moves as new certificates are indexed. On a nine-residue peptide, though, purity is the second question and identity is the first. HPLC reports what proportion of a sample is a single species, not which species it is, and with nine common amino acids that distinction is close to the whole question.

How much does DSIP cost?

The price page publishes shops in stock with the median and lowest price per milligram and the vial size behind the lowest figure, read live rather than quoted here. Compare within one vial-size band, since fixed per-vial costs fall away as fill size rises and make larger vials look cheaper per milligram than they are. Then translate to doses: community practice runs 200 to 500 mcg, so one milligram is several administrations. Those figures exclude shipping, taxes, coupon codes and bulk tiers.

Is DSIP legal to buy, and is it banned in sport?

It is not approved for human use, and as of August 2026 there is no compounding route: DSIP came off FDA's 503A Category 2 list in the April 2026 reclassification, and in July 2026 an advisory committee declined to recommend it for listing as emideltide. That vote is non-binding and FDA has not completed rulemaking on any of the seven peptides it reviewed. DSIP is not named on the WADA Prohibited List as of the 2026 List, checked August 2026.

How do I know my vial is really DSIP?

Mass spectrometry showing a mass near 848.8 daltons, on a certificate matched to your batch. With a nine-amino-acid peptide made of common residues, HPLC purity alone cannot establish identity, because the composition overlaps other small neuropeptides. Check the CAS as well, 62568-57-4, and treat a listing that publishes neither the sequence WAGGDASGE nor a mass result as unverified rather than merely undocumented.

What dose of DSIP is supported by evidence?

None is validated. The published intravenous trials dosed roughly 25 nmol/kg — about 1.5 mg for a 70 kg adult, a figure derived from the trial dose and the verified molecular weight rather than quoted in the paper — while community subcutaneous convention runs 200 to 500 mcg, roughly a third to a fifth of that exposure by a different route. The protocol most people follow has never been tested, and the protocol that was tested did not produce a significant result. The calculators convert a chosen dose into a syringe volume; no published source tells you which dose to choose.

Does the July 2026 FDA panel vote mean DSIP is banned?

No, and it does not mean it is approved either. The Pharmacy Compounding Advisory Committee is advisory: it declined to recommend emideltide for the 503A bulks list on a 6–7–1 vote, citing insufficient safety and efficacy data, and FDA has not completed rulemaking on any of the seven peptides reviewed on 23 and 24 July 2026. What it does mean is that a panel which recommended six other compounds on thin evidence, several over its own reviewers' objections, would not recommend this one.

Browse the cognitive and neuroprotective peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For per-injection volume, use the peptide dosing calculator alongside the reconstitution calculator. Compare shops through independent lab tests and community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.